GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Evoke Pharma Inc (STU:EV00) » Definitions » Inventories, Finished Goods

Evoke Pharma (STU:EV00) Inventories, Finished Goods : €0.00 Mil (As of Dec. 2023)


View and export this data going back to 2016. Start your Free Trial

What is Evoke Pharma Inventories, Finished Goods?

Evoke Pharma's quarterly finished goods declined from Jun. 2023 (€0.15 Mil) to Sep. 2023 (€0.14 Mil) and declined from Sep. 2023 (€0.14 Mil) to Dec. 2023 (€0.00 Mil).


Evoke Pharma Inventories, Finished Goods Historical Data

The historical data trend for Evoke Pharma's Inventories, Finished Goods can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Evoke Pharma Inventories, Finished Goods Chart

Evoke Pharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Inventories, Finished Goods
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Evoke Pharma Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Inventories, Finished Goods Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 0.03 0.15 0.14 -

Evoke Pharma Inventories, Finished Goods Calculation

The products in a manufacturer's inventory that are completed and are waiting to be sold.


Evoke Pharma (STU:EV00) Business Description

Traded in Other Exchanges
Address
420 Stevens Avenue, Suite 370, Solana Beach, CA, USA, 92075
Evoke Pharma Inc is a specialty pharmaceutical company focused on the development of drugs to treat gastrointestinal, or GI, disorders, and diseases. The company's product Gimoti is an investigational metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. Gimoti is a novel nasal spray formulation of metoclopramide designed to provide systemic delivery of the molecule through the nasal mucosa.

Evoke Pharma (STU:EV00) Headlines

No Headlines